Randomized phase ii open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 13, Issue 3, 2014, Pages 156-163.e2

  O'Neil, Bert H ^a   Cainap, Calin ^b   Van Cutsem, Eric ^c   Gorbunova, Vera ^d   Karapetis, Christos S ^e   Berlin, Jordan ^f   Goldberg, Richard M ^g   Qin, Qin ^h   Qian, Jiang ^h   Ricker, Justin L ^h   Fischer, Judee ^h   McKee, Mark D ^h   Carlson, Dawn M ^h   Kim, Tae Won ⁱ  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^e FLINDERS UNIVERSITY   (Australia)

^f VANDERBILT INGRAM CANCER CENTER   (United States)

^g THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^h ABBVIE INC   (United States)

ⁱ University of Ulsan College of Medicine   (South Korea)

Author keywords

ABT 869; Advanced colorectal cancer; Colon cancer; Second line; TKI

Indexed keywords

BEVACIZUMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LINIFANIB; OXALIPLATIN; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; INDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; N-(4-(3-AMINO-1H-INDAZOL-4-YL)PHENYL)-N1-(2-FLUORO-5-METHYLPHENYL)UREA; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHONIA; EPISTAXIS; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPOKALEMIA; HYPOTHYROIDISM; LEUKOPENIA; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SMALL INTESTINE PERFORATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; CHEMICALLY INDUCED; CLINICAL TRIAL; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; HAND-FOOT SYNDROME; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HAND-FOOT SYNDROME; HUMANS; HYPOTHYROIDISM; INDAZOLES; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PHENYLUREA COMPOUNDS; SURVIVAL RATE; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 84908153722     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2014.04.001     Document Type: Article

References (29)

1. A. Jemal, F. Bray, and M.M. Center Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
3. Howlander N, Noone AM, Krapcho M, et al. Previous Version: SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Updated August 20, 2012. Available at: http://seer.cancer.gov/csr/1975-2009-pops09/.
4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Colon Cancer. Available at: http://www.nccn.org/professionals/physician-gls/pdf/colon.pdf. Accessed August 16, 2012.
5. N. Tanigawa, H. Amaya, and M. Matsumura Tumor angiogenesis and mode of metastasis in patients with colorectal cancer Cancer Res 57 1997 1043 1046
6. S.I. Ishigami, S. Arii, and M. Furutani Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer Br J Cancer 78 1998 1379 1384
7. H. Kuramochi, K. Hayashi, and K. Uchida Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer Clin Cancer Res 12 2006 29 33
8. J. Sun, D.A. Wang, and R.K. Jain Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors Oncogene 24 2005 4701 4709
9. B.J. Giantonio, P.J. Catalano, and N.J. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 2007 1539 1544
10. E. Van Cutsem, E. Bajetta, and J. Valle Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma J Clin Oncol 29 2011 2004 2010
11. L.B. Saltz, L.S. Rosen, and J.L. Marshall Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy J Clin Oncol 25 2007 4793 4799
12. J. Zhou, B.C. Goh, and D.H. Albert ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside J Hematol Oncol 2 2009 33
13. D.H. Albert, P. Tapang, and T.J. Magoc Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor Mol Cancer Ther 5 2006 995 1006
14. C.I. Wong, T.S. Koh, and R. Soo Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies J Clin Oncol 27 2009 4718 4726
15. E.H. Tan, G.D. Goss, and R. Salgia Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer J Thorac Oncol 6 2011 1418 1425
16. S.S. Ramalingham, M. Shtivelband, and R.A. Soo Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous NSCLC J Clin Oncol 30 suppl 15 2012 abstract 7512
17. D. Arnold, T. Andre, and J. Bennouna Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study) J Clin Oncol 30 suppl 18 2012 abstract CRA3503
18. E. Van Cutsem, J. Tabernero, and R. Lakomy Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen J Clin Oncol 30 2012 3499 3506
19. L.B. Saltz, S. Clarke, and E. Diaz-Rubio Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
20. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
21. C.S. Fuchs, J. Marshall, and E. Mitchell Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study J Clin Oncol 25 2007 4779 4786
22. P.M. Hoff, A. Hochhaus, and B.C. Pestalozzi Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II) J Clin Oncol 30 2012 3596 3603
23. H.J. Schmoll, D. Cunningham, and A. Sobrero Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III) J Clin Oncol 30 2012 3588 3595
24. A. Carrato, A. Swieboda-Sadlej, and M. Staszewska-Skurcznska Final results from a randomized, double-blind, phase III study of sunitinib plus FOLFIRI vs placebo plus FOLFIRI in first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC) Ann Oncol 21 suppl 6 2010 abstract O-0026
25. J.R. Hecht, T. Trarbach, and J.D. Hainsworth Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma J Clin Oncol 29 2011 1997 2003
26. J.R. Infante, A.L. Cohn, and T.R. Reid A randomized phase II study comparing mFOLFOX-6 combined with axitinib or bevacizumab or both in patients with metastatic colorectal cancer (mCRC) J Clin Oncol 29 suppl 4 2011 abstract 485
27. A. Grothey, C.E. Van, and A. Sobrero Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 2013 303 312
28. C. Porta, G. Procopio, and G. Carteni Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases BJU Int 108 2011 E250 E257
29. R.S. Kerbel Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results J Clin Oncol 19 2001 45S 51S